Bioventus Inc在提交给美国证券交易委员会（SEC）的文件中表示，针对Exogen骨骼愈合系统相关报销政策的调整，预计不会对公司2026财年的财务状况产生实质性影响。
该医疗技术公司评估后认为，尽管医疗支付环境可能存在变化，但其核心业务运营和财务表现预计将保持稳定。公司管理层已将此因素纳入财务预测考量，并确信现有业务模式能够适应相关的政策变动。
Bioventus Inc在提交给美国证券交易委员会（SEC）的文件中表示，针对Exogen骨骼愈合系统相关报销政策的调整，预计不会对公司2026财年的财务状况产生实质性影响。
该医疗技术公司评估后认为，尽管医疗支付环境可能存在变化，但其核心业务运营和财务表现预计将保持稳定。公司管理层已将此因素纳入财务预测考量，并确信现有业务模式能够适应相关的政策变动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.